• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Rare disease biotech Rallybio files for a $100 million IPO

firstwordpharmaJuly 06, 2021

Tag: Rallybio , IPO , FNAIT

Rallybio has filed with the SEC to raise up to $100 million in an initial public offering, reported Renaissance Capital.

The company is currently advancing its lead program, RLYB211, in a Phase I/II trial for the treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

RLYB211 is a polyclonal anti-HPA-1a antibody and is expected to report data from its Phase I/II trial in this month.

The company also has four preclinical programs, one of which, RLBY212, is also being developed for the treatment of FNAIT, and two of which are being developed to treat complement dysregulation diseases.


Previous:Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases

Next:Ultimovacs Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Rare disease biotech Rallybio files for a $100 million IPO | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Dipotassium Phosphate Trihydrate DKP

Dipotassium Phosphate Trihydrate DKP
Alpha Lipoic Acid

Alpha Lipoic Acid
Hot Sale Dipotassium glycyrrhizinate

Hot Sale Dipotassium glycyrrhizinate
cationic liposome DLin-MC3-DMA丨1224606-06-7

cationic liposome DLin-MC3-DMA丨1224606-06-7
Tripossium Glycyrrhiznate

Tripossium Glycyrrhiznate
LDS-L1 TANGENTIAL FLOW FILTRATION/Liposome dialysis / liposome ultrafiltration

LDS-L1 TANGENTIAL FLOW FILTRATION/Liposome dialysis / liposome ultrafiltration
DIPOTASSIUM CETYL PHOSPHATE

DIPOTASSIUM CETYL PHOSPHATE

Tripotassium glycyrrhizinate

Tripotassium glycyrrhizinate
Bis-TBDMS-trans-calcipotriol

Bis-TBDMS-trans-calcipotriol

Membrane extruder/Liposomes extruder/1

Membrane extruder/Liposomes extruder/1

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service